Save time and jump to the most important pieces.
3 - Helix Acquisition Corp. II (0001869105) (Issuer)
4 - Helix Acquisition Corp. II (0001869105) (Issuer)
4 - Helix Acquisition Corp. II (0001869105) (Issuer)
Total proceeds, assuming no redemptions, are expected to be $450 million, combining funds held in the Helix Acquisition Corp. II trust account and a private investment in public equity (PIPE) financing Leading institutional investors commit approximately $260 million through a PIPE led by Cormorant Asset Management Business combination is expected to be completed in the third quarter of 2025 The combined entity will be named BridgeBio Oncology Therapeutics (BBOT) and will be advancing a next-generation pipeline of therapies for patients with RAS and PI3Kα malignancies TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics ("BBOT"), a clinical-stage biopharmaceutical company advanci
10-K - Helix Acquisition Corp. II (0001869105) (Filer)
SCHEDULE 13D/A - Helix Acquisition Corp. II (0001869105) (Subject)
425 - Helix Acquisition Corp. II (0001869105) (Subject)
SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)
SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)
SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)